Skip to main content

Table 4 Generalized Estimated Equation saturated model: Associations between virologic and immunologic failure with baseline and clinical characteristics

From: Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania

Variable

Virologic failure Odds ratio* (OR)

95% CI

p-value

Immunologic failure Odds ratio* (OR)

95% CI

p-value

Month 6

1.54

0.65-3.67

0.329

3.49

0.48-25.66

0.219

Month 12

9.64

2.92-31.86

0.000

6.57

1.17-36.90

0.032

Month 24

45.88

10.07-208.96

0.000

9.78

1.16-81.30

0.035

Age

0.91

0.78-1.05

0.197

0.78

0.47-1.29

0.333

Education

0.92

0.82-1.04

0.191

0.89

0.65-1.00

0.053

Not married

2.88

0.46-17.96

0.257

0.02

0.00-18.35

0.271

Gravidity

1.49

0.68-3.25

0.317

0.86

0.42-1.87

0.746

Parity

0.74

0.30-1.80

0.506

1.08

0.34-3.43

0.898

Disclosed HIV status

0.84

0.17-4.18

0.829

4.94

0.58-42.19

0.144

Partner HIV unknown

0.75

0.19-2.95

0.675

3.63

0.07-181.81

0.519

Partner HIV positive

4.21

0.60-29.38

0.147

1.94

0.03-139.79

0.761

Hemoglobin

0.75

0.54-1.03

0.071

0.32

0.07-1.47

0.143

Not adherent month 6

2.15

0.57-8.09

0.256

2.85

0.20-41.10

0.442

Not adherent month 24

10.01

2.29-43.66

0.002

30.98

1.31-733.91

0.033

  1. *Odds Ratio adjusted for all variables in the table.